SCHEMBL1245535

SCHEMBL1245535

O=C(Cl)c1cc(C(=O)Cl)[nH]n1

nearest known ligand 0.47

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.47
HCAR2 Q8TDS4 11/20 0.38
DAO P14920 1/20 0.38
CYTH3 O43739 1/20 0.34
BTK Q06187 1/20 0.34
EPN1 Q9Y6I3 1/20 0.34
HCAR3 P49019 1/20 0.34
ALPL P05186 4/20 0.34
CA12 O43570 2/20 0.34
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27921698 0.77
SCHEMBL22939364 0.77
SCHEMBL4422664 0.76
SCHEMBL4420054 0.76
SCHEMBL28016552 0.76
SCHEMBL3452780 0.72 DYRK1A (0.34) MAPK1ALPLCA12TP53
SCHEMBL21964595 0.72 HCAR2 (0.34) MAPK1HCAR2DAOCYTH3BTK
SCHEMBL27865500 0.71 ALPL (0.38) MAPK1HCAR2HCAR3ALPLCA12
SCHEMBL11215462 0.71 KMT2A (0.46) HCAR2DAO
SCHEMBL3053796 0.71 ALOX15 (0.51) MAPK1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025026556-A1 CROSSLINKERS PREFERE RESINS HOLDING GMBH (DE) 2025-02-06 WO disclosed
WO-2023287736-A1 NOVEL BIS-AMIDE CONTAINING COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2023-01-19 WO disclosed
WO-2023287736-A1 NOVEL BIS-AMIDE CONTAINING COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2023-01-19 WO disclosed
US-20160075667-A1 COMPOSITIONS AND METHODS FOR CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) MAGNETIC RESONANCE IMAGING (MRI) UNIV JOHNS HOPKINS (US) 2016-03-17 US disclosed
WO-2014182538-A1 COMPOSITIONS AND METHODS FOR CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) MAGNETIC RESONANCE IMAGING (MRI) THE JOHNS HOPKINS UNIVERSITY (US) 2014-11-13 WO disclosed
US-20130266590-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2013-10-10 US disclosed
US-8445440-B2 Dimeric IAP inhibitors NOVARTIS AG (CH) 2013-05-21 US disclosed
US-20110206690-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-08-25 US disclosed
WO-2011021707-A1 LIGHT-DIFFUSING SHEET FUJIFILM CORPORATION (JP) 2011-02-24 WO disclosed
US-6392009-B1 POLYBENZIMIDAZOLE, POLYBENZOXAZOLE, POLYBENZOTHIAZOLE; HEAT AND OXIDATION RESWISTANCE THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE 2002-05-21 US disclosed
US-4118232-A Photographic material containing sulphonic acid group containing disazo dyestuffs CIBA-GEIGY AG (CH) 1978-10-03 US disclosed
US-4051123-A Sulfonic-acid-group containing disazo dyestuffs CIBA-GEIGY AG (CH) 1977-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130266590-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 MAPK1 1491/4885HCAR2 3443/4885DAO 2809/4885
US-20160075667-A1 COMPOSITIONS AND METHODS FOR CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) MAGNETIC RESONANCE IMAGING (MRI) SLC46A1, SLC5A7, SLCO1B1 MAPK1 2552/4885HCAR2 879/4885DAO 2903/4885
US-20110206690-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 MAPK1 1470/4885HCAR2 3138/4885DAO 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.